Hox genes have been identified in chromosomal translocations involving the nucleoporin gene NUP98. Though the resulting chimeric proteins directly participate in the development of leukemia, the long latency and monoclonal nature of the disease support the requirement for secondary mutation(s), such as those leading to overexpression of Meis1. Models to identify such events and to study leukemic progression are rare and labor intensive. Herein, we took advantage of the strong transforming potential of NUP98-HOXD13 or NUP98-HOXA10 to establish preleukemic myeloid lines from bone marrow cells that faithfully replicate the first step of Hox-induced leukemogenesis. These lines contain early granulomonocytic progenitors with extensive in vitro self-renewal capacity, short-term myeloid repopulating activity and low propensity for spontaneous leukemic conversion. We exploit such lines to show that Meis1 efficiently induces their leukemic progression and demonstrate a high frequency of preleukemic cells in the cultures. Furthermore, we document that the leukemogenic potential of Meis1 is independent of its direct binding to DNA and likely reflects its ability to increase the repopulating capacity of the preleukemic cells by increasing their selfrenewal/proliferative capacity. The availability of lines with repopulating potential and capacity for leukemic conversion should open new avenues for understanding progression of Hox-mediated acute myeloid leukemia.
Introduction
Hox genes were first implicated in leukemia by their observed aberrant expression and by translocations involving their cofactor Pbx1 and upstream regulator MLL.
1 Abd-B Hox genes are also directly implicated in chromosomal translocations 2, 3 and are the most common fusion partners of nucleoporin 98 (NUP98). Direct evidence of the ability of native and NUP98-Hox fusions to induce myeloproliferative disease and/or acute myeloid leukemia (AML) has been demonstrated in murine bone marrow (bm) transplantation models. [4] [5] [6] [7] Moreover, we have recently reported that leukemogenic potential is a redundant characteristic of Abd-B class Hox genes (either native or as NUP98 fusion partners), a feature correlated with their common ability to block myeloid differentiation. 4 The long latency of Hox-mediated AML described in the mouse model 4, 6, 8 strongly indicates that additional genetic events are required for full leukemic progression. Indeed, a large body of data supports the theory that Hox-containing fusions, as with most transcription factor-containing fusion oncogenes, alter the growth and differentiation of early hematopoietic precursors, leading to the establishment of a preleukemic population of cells that are then susceptible to the acquisition of cooperating mutations. 9 This is reinforced by the finding that overexpression of the Hox cofactor Meis1 cooperates with multiple native and NUP98-Hox fusion genes to accelerate the onset of AML. 4, 6, 10 Interestingly, Meis1 is not leukemogenic on its own. However, its important role in normal hematopoiesis is supported by its preferential expression in the hematopoietic stem cell compartment 11 and by the multiple hematopoietic defects observed in Meis1-deficient mice. 12 Moreover, in vitro studies have showed that Meis1 can affect myeloid differentiation 13, 14 and proliferation. 14 The mechanism(s) underlying the role of Meis1 in the progression of Hox-mediated leukemia, however, is still unclear.
The discovery and functional characterization of genetic components acting in collaboration with native-and fused-Hox proteins, and the identification of the cell population(s) targeted by these mutations are central to the understanding of Hoxmediated AML and to the identification of suitable therapeutic targets. To this end, improved tools to investigate and follow the progression of Hox-induced leukemia would be valuable. Several laboratories have taken advantage of the ability of homeobox-containing genes to block myeloid differentiation, and have thereby obtained primary myeloid precursors that can be maintained in culture for long periods of time, providing unlimited numbers of cells. [15] [16] [17] [18] Although these lines have proven useful for the study of homeoproteins and their cofactors, their utility as models to investigate leukemic progression is unknown, as they have either not yet been characterized in vivo [16] [17] [18] or have no reported potential to be converted into AML-inducing cells. 15 Thus, the availability of lines with documented repopulating potential and capacity for leukemic conversion would open a new path for the understanding of the progression of Hox-mediated AML.
In this study, we used potent leukemogenic Hox-fusion genes to establish transplantable preleukemic cells that have characteristics of committed short-term myeloid repopulating cells. Moreover, we show that Meis1 can convert these into aggressive AML-inducing cells with high frequency, an indication that Meis1 can induce the leukemic conversion of Hoxtransformed committed myeloid progenitors. This novel 'multistep' leukemogenesis model provides a new tool towards the identification of Hox-collaborating genes and the functional characterization of their role in leukemic progression. Moreover, we have exploited this system to further clarify the mechanism(s) underlying the role of Meis1 in leukemic progression and show that it involves its ability to increase the in vivo repopulating capacity of the preleukemic cells and, surprisingly, it is essentially independent of the direct binding of its homeodomain to DNA.
Materials and methods

Retroviral vectors and engineering of novel NUP98-Hox fusion genes
The following vectors were previously described: 4 MSCV-IRES-GFP (GFP virus), MSCV FLAG-NUP98-HOXD13 IRES eGFP (ND13 virus), MSCV NUP98-HOXA10 IRES (NA10 virus) and MSCV HA-Meis1a IRES-YFP (Meis1 virus). The MSCV-HAMeis1(N51S)-YFP (Meis1(N51S) virus) was constructed by replacing the HA-Meis1 portion of the Meis1 virus by a HAMeis1 cDNA containing an asparagine to serine substitution at position 51 of the homeodomain (kindly provided by Dr Mark Featherstone, McGill University, Montreal, Quebec). 19 
Establishment of long-term NUP98-Hox culture lines
Primary mouse bm cells were transduced as previously described. 8 The lines were established by the continuous growth of polyclonal transduced bm cells for a period X4 weeks in DMEM supplemented with 15% FBS, 10 ng/ml hIL-6, 6 ng/ml mIL-3 and 100 ng/ml mSF. All culture media and growth factors were obtained from StemCell Technologies Inc. (Vancouver, BC, Canada). Cells were maintained at a cell density inferior to 2 Â 10 6 /ml. 4 
In vitro assays
Cell proliferation was assessed in the same media described above. Differentiation of clonogenic progenitors was analyzed and scored in methylcellulose cultures, as previously described. 4 Tests of growth in single cytokines were carried out in liquid suspension culture with either IL-3 (6-10 ng/ml), mSF (50 ng/ml), GM-CSF (10 ng/ml), G-CSF (10 ng/ml) or M-CSF (1/50 dilution of in house COS-produced M-CSF) in DMEM with 10% FBS. The cells were cultured for 3-5 days in G-CSF, 7-8 days in M-CSF and up to 3 weeks in GM-CSF.
Southern blot analysis
Genomic DNA was isolated using DNAzol reagent as recommended by the manufacturer (Invitrogen, Carlsbad, CA, USA), and Southern blot analyses were performed as previously described. 4 Further details are provided in the respective figure legends.
Statistical analysis
Data were statistically tested using the t-test for dependent or independent samples (Microsoft Excel). Differences with P-values o0.05 were considered statistically significant.
Results
Expression of NUP98-HOXD13 or NUP98-HOXA10 leads to the establishment of early myeloid progenitor lines (NUP-Hox lines) that retain limited in vivo repopulating potential
We have previously documented that the expression of ND13 or NA10 blocks the differentiation of bm cells in vitro, yielding a highly homogeneous population of immature myeloid cells after 2-3 weeks of liquid culture. 4 To determine whether this phenomenon could be exploited to obtain cell lines representing a preleukemic stage that could model the first step in Hoxmediated leukemia, we transduced fresh bm cells with ND13 or NA10 and analysed these after extensive time in culture. ND13 and NA10-transduced bm cells (GFP þ ) predominated the cultures within 3 weeks and yielded a sustained high cell output ( Figure 1a ). In contrast, the control GFP þ -and Meis1-transduced cells eventually differentiated and ceased dividing after 3 weeks (Figure 1a) .
In all, three polyclonal independent NUP-Hox lines were generated for NA10 or ND13 (NA10-or ND13-1, -2 and -3). Subclones of the NA10 (NA10-1.1, -1.4, -1.7 and -3.4) and ND13 lines (ND13-2.15 and ND13-3.1) were also established by expanding early myeloid colonies from methylcellulose cultures. Integration of full-length NUP-Hox provirus was confirmed by Southern blot analysis (data not shown). The lines were primarily comprised of early myeloid progenitors, as evident by: (1) a high proportion of primitive blast-like cells, negative for an array of lineage markers (Gr-1, Mac-1, Ter-119, B220, CD4, CD8), but expressing low levels of c-Kit; (2) sustained long-term in vitro growth (over 100 days, not tested further) and (3) sustained high plating efficiency (combined mean of all lines of 26.9710.8% (nX6)). All lines remained cytokine-dependent throughout the period of observation.
To investigate whether these lines retained engraftment and repopulating potential consistent with primitive hematopoietic cells, lethally irradiated mice were injected with 7.5 Â 10 5 cells from each line (the ND13-3 line was not tested in this context) after various durations of culture. As shown in Figure 1b Figure 1d shows that the reconstitution potential of representative lines and subclones is limited, as the proportion of GFP þ wbc diminished steadily over time. Although GFP þ wbc were still detectable 13 weeks post-transplant in numerous recipients, they eventually declined below 1% for the majority of the lines. Reconstitution potential was a stable property of lines maintained for extended times in culture, as shown in Figure 1e for the line ND13-1 transplanted after 30 or 60 days culture. Taken together, the engraftment properties and lineage commitment observed for all lines and subclones are consistent with the lines having short-term myeloid-restricted reconstitution activity.
Of the 68 mice transplanted with the NUP-Hox lines (see Figure 1 legend for details), none developed leukemia over a 5-month observation period, at which time, in the majority of the mice, the engraftment levels had dropped to less than 1% (17 of 29 NA10 mice and 27 of 30 ND13 mice confirmed GFP . A total of 17 mice were transplanted with NA10-1, 10 for NA10-2, six for NA10-3, five for NA10 3.4, nine for ND13-1, 11 for ND13-2 and seven for ND13 2.15 (three for ND13-3 not shown).
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N Pineault et al negative). However, several mice which had long-term engraftment developed lethal myeloproliferative-like disease (MPD) or AML. These included one of the mice transplanted with the ND13-1 kept in culture for 30 days before transplantation (Figure 1e inset), which died 307 days post-transplant of a MPD with evident anemia (o2 Â 10 9 rbc/ml) and elevated wbc (73 Â 10 6 GFP þ cells/ml). In addition, six of the NA10-2 transplants succumbed to AML or MPD with a median survival of 205 days. Two of these six mice had evident AML characterized by elevated wbc (477 Â 10 6 wbc/ml), reduced rbc (o6 Â 10 9 rbc/ml), splenomegaly (0.770.2 g) and elevated myeloid blasts in bm (3378%). The last recipient analyzed developed a lethal MPD similar to that documented with line ND13-1 (high wbc counts but no significant elevation in blasts). The leukemias were transplantable, with all recipients quickly succumbing to disease (27- 41 days) .
Collectively, these results demonstrate that the NUP-Hox lines are early myeloid progenitor cells that retain limited but significant myeloid repopulating potential. The fact that the lines with the longest repopulation capacity induced leukemia further suggests that the NUP-Hox lines are truly preleukemic cells that, with time, can be converted into AML-inducing cells, probably through the acquisition of secondary mutations.
Meis1 can convert NUP-Hox lines into AML-inducing cells with high frequency
Meis1 is known to induce rapid AML in collaboration with multiple native-and fusion-Hox genes when co-transduced into fresh bm cells. 4, 10, 20 To determine whether Meis1 can induce leukemic progression of preleukemic NUP98-Hox-induced cells, we transduced NUP-Hox lines, at various times after establishment (28-85 days), with the Meis1-YFP virus and transplanted them into lethally irradiated mice (Figure 2a (Figure 3a) and Southern blot analysis (Figure 3b ) of leukemic marrow, respectively. The AML phenotype was confirmed by morphologic analysis of bm preparations, which showed 420% myeloid blasts ( Table 1 ). The myeloid nature of the leukemic cells was confirmed by flow cytometry, which revealed that for the majority of mice analyzed (n ¼ 11) the leukemic bm cells were Mac-1 þ (B40%) and Gr-1 þ (B20%), but were all essentially negative (o1%) for Sca-1, B220, CD4 and CD8 (data not presented). The derived clones of the NUPHox lines also showed the same property of leukemogenic conversion by Meis1 (Table 1 ). This phenomenon was highly reproducible, as the majority of the lines were tested in two independent experiments and up to four times. The strong leukemogenic potential of the lines was further substantiated by the death of all the mice transplanted with more than 3000 NUP-Hox cells complemented with Meis1.
In order to assess the frequency of cells with leukemic conversion potential (preleukemic cells), we transduced the NA10-1 line (maintained in culture for 54 days) with Meis1 and injected various numbers of nonpurified cells harvested immediately after infection, using the principle of the limiting dilution assay. In two independent experiments, all mice transplanted with as few as 20-27 doubly transduced cells succumbed to leukemia (representative experiment shown in Figure 4a ). Analysis of wbc in mice injected with 27 cotransduced cells at different times after transplantation clearly demonstrated rapid in vivo proliferation of the Meis1-transduced NA10 cells (Figure 4b ). Southern blot analysis demonstrated the presence of the Meis1 and the NA10 provirus in all leukemias (Figure 4c top panel) , and Meis1 proviral integration patterns (Figure 4c bottom panel) consistent with polyclonal leukemias in most mice even in one mouse injected with 27 cotransduced cells (multiple bands of varying intensity for lanes 2, 3, 6 and 7). However, there were also monoclonal leukemias (single band in lanes 5 and 8).
Taken together, these results demonstrate that the ND13 and NA10 lines contain a high frequency (B5%) of preleukemic transplantable cells that can be converted to aggressive AMLinducing cells with a single additional engineered genetic 'hit'.
The ability of Meis1 to induce the leukemic progression of the NUP-Hox lines reflects its capacity to increase their in vivo repopulating activity and is independent of its binding to DNA The mechanism by which Meis1 collaborates with Hox to induce overt leukemia is not understood. Thus, we proceeded to investigate whether increased Meis1 expression could potenti- Leukemic conversion of NUP98-Hox lines by Meis1 N Pineault et al ate the differentiation block induced by NUP98-Hox fusions. As previously described for short-term ND13 bm cultures, 4 the majority of the cells from the NUP-Hox lines failed to undergo granulocytic differentiation (o20%) in the presence of G-CSF, but did differentiate into macrophages (470%) with M-CSF. Interestingly, increased Meis1 expression did not appear to induce further differentiation block in any of the cytokines tested (GM-CSF, M-CSF or G-CSF, (n ¼ 2), data not shown). These results are consistent with those previously reported for NUP98-HOXA9. 16 While the differentiation properties of NUP-Hox lines were not overtly affected by Meis1 in vitro, Meis1-transduced ND13 cells (lines 1, 2 and 2.15 were tested) consistently produced a greater number of colonies than the parental cells in primary methylcellulose cultures (Figure 5a (Po0.05) ) and in secondary plating (data not shown). This growth potentiation became more evident in vivo, when we compared the engraftment and expansion of the ND13-2 line and the ND13-2.15 clonal subline, with or without ectopic Meis1 expression. Engraftment, measured by detection of Ly5.1 þ cells, was comparable for lines with or without Meis1 co-expression at early times posttransplant (6 days) in peripheral blood (pb), bm and spleen, suggesting that the initial seeding efficiency was not markedly altered by Meis1 (Figure 5b ). However, a striking difference was readily detectable between both groups 20 days post-transplant, with both Meis1-transduced lines showing a much greater expansion, as apparent from the increased proportion of donorderived cells in the pb, bm and spleen (Figure 5b ) and the increased yield of cell line-derived myeloid progenitors in the bm and spleen, detectable in clonogenic assays (Figure 5c ). These findings are consistent with a potent ability of Meis1 to enhance the repopulating potential of the NUP-Hox preleukemic cells, probably by increasing their self-renewal/proliferative capacity.
In order to gain further insight into the molecular mechanism(s) underlying the role of Meis1, we exploited the NUP-Hox lines to investigate whether the DNA-binding activity of Meis1 is required for the progression of Hox-associated leukemia. This was directly tested by transducing the ND13 and NA10 lines with a Meis1 mutant, Meis1(N51S), previously shown to be incapable of binding to DNA, due to an asparagines-to-serine substitution in the residue 51 of its homeodomain. 19 The subclones ND13-2.15 and NA10-3.4 lines were first used to Figure 3 Co-expression of the GFP and YFP reporter genes in leukemic cells isolated from sick recipients. (a) Upper FACS profiles: GFP and YFP expression in the ND13-2 cell line before and after infection with Meis1 (M1). The ND13-2 þ Meis1 cells were derived from the expansion of GFP þ /YFP þ sorted Meis1-transduced ND13-2 cells. Lower FACS profiles: GFP and YFP expression in bm cells isolated from a normal mouse (CTL) or moribund mice that were transplanted with ND13-2 or NA10-3 cells additionally transduced with Meis1 (representative profile shown). (b) Southern blot analysis of genomic DNA from the bm of moribund mice confirmed the presence of NUP98-Hox and Meis1 proviruses (total time spent in culture prior to injection also shown). Genomic DNA was digested with XbaI, which cuts in both retroviral LTRs, and the eGFP cDNA was used as proviral probe. Table 1 Hematopoietic characteristics of diseased mice transplanted with the NUP-Hox lines transduced with Meis1 (mean7s.d.)
reduce the potential differences that might arise from the polyclonal lines. Surprisingly, the strong synergistic-leukemogenic property of Meis1 was essentially preserved in the Meis1(N51S) mutant. These results were additionally confirmed with 2 ND13 and 2 NA10 polyclonal lines, for which all 18 transplants developed leukemia ( Figure 6 and data not shown).
As apparent in Figure 6 , the development of leukemia in mice transplanted with the equivalent number of co-transduced cells was slightly delayed with the mutated Meis1(N51S), compared to the normal Meis1 (Po0.04). Nonetheless, all Meis1(N51S)-transplanted mice succumbed to leukemia (Figure 6 ), strongly supporting the notion that the Meis1 DNA-binding activity is largely dispensable for its synergistic-leukemogenic property.
Discussion
In the study described here, we document that NA10 and ND13 support the in vitro growth of transplantable early myeloid progenitor cells that display in vitro and in vivo properties consistent with a Hox-mediated preleukemic state. Indeed, two of the cell lines showed the potential to cause a MPD or AML after long latency. Moreover, complementation experiments carried out with Meis1 provided strong evidence of a high percentage of preleukemic cells in all lines, thus demonstrating the ability of Meis1 to induce the leukemic progression of committed myeloid progenitors. Furthermore, we exploited this novel preleukemic model to show that the leukemic conversion capacity of Meis1 is independent of its direct binding to DNA and involves its ability to increase the in vivo repopulating capacity of the preleukemic cells. Myeloid progenitors immortalized by native or fused homeobox-containing genes have previously been described and successfully exploited to study Hox-mediated block in differentiation, but their value in studying leukemic progression is limited. Indeed, Calvo et al have established myeloid cell lines immortalized by ectopic expression of HOXA9 17 or NUP98-HOXA9. 16 However, in their experimental settings, HOXA9-immortalized cells did not produce AML upon expression of Meis1. A conceivable explanation for this discrepancy is that the lines possess distinct properties originating from the functional divergences between HOXA9 and the NUP98-Hox genes used in our study. In addition, it is possible that whereas our cytokine cocktail allows the maintenance of cells with leukemogenic potential, GM-CSF alone, as used by Calvo et al, does not. Support for this comes from our observation of decreased leukemogenic activity in Meis1-transduced NUP-Hox cells grown in GM-CSF alone (only two mice out of eight became sick; Pineault and Humphries, unpublished results). Additional homeobox-immortalized myeloid progenitors have been described with HOX11 by Hawley et al, 15 and though these showed long-term myeloid reconstitution, they lacked leukemogenic activity. Therefore, the NUP-Hox lines share some of the properties of several other Hox-immortalized cell lines, but they also possess the unique property of AML-inducing conversion following adequate complementation. Conversion of a nonleukemic NOTCH-1 line into AML-inducing cells was recently reported with AML1-ETO, though the disease latency The proto-oncogene Meis1 was first isolated, together with HoxA7 and HoxA9, as a common site of viral integration involved in myeloid leukemia in BXH-2 mice. 22 Moreover, analysis of Meis1 and Hox expression showed their coexpression in the most primitive hematopoietic subpopulations 11 and in human AML. 23 Our findings that Meis1 can convert Hox-immortalized myeloid progenitors into AMLinducing cells indicate that the co-expression of Hox and Meis1 in hematopoietic stem cells is not essential for leukemogenesis, and thus provides novel experimental support for a two-step model for Hox-Meis1-mediated leukemia.
Previous attempts to understand the cellular mechanisms underlying the role of Meis1 in Hox-mediated AML have been performed using in vitro settings, and showed that Meis1 can affect myeloid differentiation 13, 14 and proliferation. 14 In our in vitro studies, Meis1 did not seem to block differentiation and only slightly increased self-renewal, consistent with the reported lack of effect of Meis1 on NUP98-HOXA9 immortalized lines. 16 Surprisingly, in our in vivo experiments, Meis1 strongly increased the repopulating potential of otherwise short-term repopulating NUP-Hox cell line-derived myeloid progenitors. This effect could be mediated by the ability of Meis1 to increase the self-renewal/proliferative capacity of the cells, a possibility that is in agreement with the greater plating efficiency of Meis1-transduced ND13 lines and analysis of Meis1-null mice, where defects in HSC self-renewal/proliferation activity were reported. 12 Taken together, our findings on the role of Meis1 in Hox-mediated leukemia are in line with the hypothesis that, in leukemia, genes that block differentiation cooperate with genes that stimulate self-renewal and/or cell division. 24 Further support for the collaboration of Hox genes with growthpromoting oncogenes comes from the strong conversion of the NUP-Hox lines into AML-inducing cells by BCR-ABL (Pineault and Humphries, unpublished results).
The molecular mechanisms responsible for the collaboration of Meis1 with native-and fused-Hox genes in leukemic transformation are not known. Meis1 was originally described as a Hox cofactor that alters Hox-DNA-binding specificity and affinity, and increases Hox-transcriptional activity. 25, 26 Meis1 associates with Pbx and Hox proteins in myeloid cells, 26 in which Meis1 directly interacts on DNA with Hox proteins from paralog group 9-13, or indirectly associates with paralogs 1-8 through Pbx 25 independent of direct DNA binding. In Drosophila, studies of the Meis1 homolog Homothorax indicate that its direct binding to DNA is context dependent. Indeed, mutations that alter or delete the Homothorax homeodomain cause only partial homeotic transformations in the peripheral 
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N Pineault et al nervous system, 27 but they abolish functions such as suppression of eye and leg development. 28 We have already reported that Meis1 can collaborate with Hox proteins that contain neither Meis1-nor Pbx-binding domains; 4 this strongly rules out the possibility that the role of Meis1 is mediated through its binding to the ectopically expressed Hox, either directly or indirectly through Pbx. The new data presented here indicate that the leukemogenic conversion potential of Meis1 is not absolutely dependent on its capacity for direct binding to DNA, although this activity may modulate its collaborative potency, as suggested by the longer disease latency seen in mice transduced with the Meis1 mutant that is unable to bind DNA.
In conclusion, we have described here a system for reproducibly generating NUP98-Hox-induced cell lines that have both short-term repopulating activity and a high frequency of preleukemic cells (B5%). The demonstrated ability of Meis1 to efficiently trigger leukemic progression of such lines provides a new avenue to explore further the mechanisms underlying Meis1's important role in leukemogenesis. Additionally, this model should facilitate the future identification and characterization of other cooperative genes involved in the progression of Hox-mediated leukemia.
